Is iShares Biotechnology ETF ( IBB ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
This biotech's innovative approach could pay rich dividends down the road.
3 Fantastic Growth Stocks to Buy in August
Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years.
Is This Beaten-Down Stock a Buy on the Dip?
It's the second time this year the stock has slumped significantly in one day, and it might represent another attractive entry point.
2 Growth Stocks That Are No-Brainer Buys Right Now
These stocks have outperformed broader equities over the past decade and still have room to run.
Vertex Pharmaceuticals Incorporated ( VRTX ) Is a Trending Stock: Facts to Know Before Betting on It
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
[Latest] Global AI in Synthetic Biology Market Size/Share Worth USD 192.95 Billion by 2034 at a 28.63% CAGR: Custom Market Insights ( Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis )
Austin, TX, USA, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Custom Market Insights has published a new research report titled "AI in Synthetic Biology Market Size, Trends and Insights By Technology ( Gene Synthesis, Genome Editing, Synthetic Biology Tools, Bioinformatics ) , By Application ( Healthcare ...
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?
CRSP's Casgevy records a 114% sales jump sequentially in Q2, fueling optimism for sustained revenues and long-term growth.
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today - Vertex Pharmaceuticals ( NASDAQ:VRTX )
Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 8.34% on an annualized basis producing an average annual return of 16.94%. Currently, Vertex Pharmaceuticals has a market capitalization of $96.01 billion.
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know - Vertex Pharmaceuticals ( NASDAQ:VRTX )
Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals VRTX revealed 27 unusual trades. Delving into the details, we found 29% of traders were bullish, while 59% showed bearish tendencies.
The Smartest Growth Stocks to Buy With $1,000 Right Now
There's no guarantee that any stock will beat the market, but the chances look good for these three.
1.95M Reasons To Be Bullish On Vertex Pharmaceuticals Stock - Vertex Pharmaceuticals ( NASDAQ:VRTX )
On August 7, a substantial insider purchase was made by BRUCE SACHS, Board Member at Vertex Pharmaceuticals VRTX, as per the latest SEC filing. What Happened: SACHS's recent move, as outlined in a Form 4 filing with the U.S.
5 Top Stocks to Buy in August
Even with the S&P 500 near an all-time high, there are plenty of compelling growth, dividend, and value stocks to buy now.
The Best Stocks to Invest $1,000 In Right Now
Market volatility could increase in the months ahead, but these stocks should hold up well.
Entrada ( TRDA ) Q2 Revenue Drops 98%
Entrada Therapeutics ( NASDAQ:TRDA ) , a biotechnology company developing intracellular therapies for rare neuromuscular diseases, reported second quarter 2025 financial results on August 6, 2025. The main news from the release was a sharp drop in revenue from collaboration activities and a ...
Vertex Pharmaceuticals Unusual Options Activity - Vertex Pharmaceuticals ( NASDAQ:VRTX )
Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals VRTX revealed 55 unusual trades. Delving into the details, we found 29% of traders were bullish, while 54% showed bearish tendencies.
7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip
There's more good news than bad news for this big biotech stock.
Weakness In Vertex Stock Seen As Buying Opportunity - Vertex Pharmaceuticals ( NASDAQ:VRTX )
VX-993 fails to show statistical pain relief in the Phase 2 bunionectomy study, halting further monotherapy development. Vertex Q2 revenue rises 12% Y/Y to $2.97 billion, beating estimates. The next correction is closer than you think. Find out how Tom Gentile plans to trade it, live on Wednesday.
These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results - Vertex Pharmaceuticals ( NASDAQ:VRTX )
Vertex Pharmaceuticals Inc VRTX reported better-than-expected earnings for the second quarter after the market close on Monday. The company's revenue came in at $2.97 billion versus estimates of $2.90 billion. Adjusted EPS came in at $4.52, versus estimates of $4.29.
CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption
CRISPR Therapeutics posts a wider second-quarter loss tied to Sirius deal costs, while Casgevy adoption gains momentum across global markets.
VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal
Vertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal.
Inspire Medical Systems, Ichor Holdings, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Inspire Medical Systems ( NYSE:INSP ) , Ichor Holdings ( NASDAQ:ICHR )
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Tuesday. Shares of Inspire Medical Systems, Inc. INSP fell sharply in pre-market trading after the company reported second-quarter results and cut its FY25 guidance below estimates.
Up 50% in 3 Months, Is This Stock Still a Buy?
This biotech's innovative ways might eventually pay off.
Why Palantir Technologies Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket - Agilon Health ( NYSE:AGL ) , Adaptimmune Therapeutics ( NASDAQ:ADAP )
Shares of Palantir Technologies Inc. PLTR rose sharply in pre-market trading after the company reported better-than-expected financial results for the second quarter and raised its full-year guidance. Palantir reported second-quarter revenue of $1.004 billion, beating analyst estimates of $939.71 ...
Selloff? What Selloff? Monday Market Rebound
Palantir is way up after reporting Q2 results Monday afternoon, while HIMS and VRTX are way off highs.
Vertex Pharmaceuticals ( VRTX ) Surpasses Q2 Earnings and Revenue Estimates
Vertex (VRTX) delivered earnings and revenue surprises of +6.60% and +2.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals Stock Falls on Q2 Earnings, VX-993 Trial Results - Palantir Technologies ( NASDAQ:PLTR )
Vertex beats analyst estimates on the top and bottom lines in the second quarter. Vertex announces treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint in a Phase 2 study. The market's back, and these 3 income stocks are thriving. See them here→
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
-CASGEVY® momentum building. >75 authorized treatment centers ( ATCs ) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions. positioning the program for strong future ...
Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Vertex Pharmaceuticals ( NASDAQ:VRTX )
Vertex Pharmaceuticals Incorporated VRTX will release earnings results for the second quarter, after the closing bell on Monday, Aug. 4. Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.25 per share, versus a year-ago loss of $12.83 per share.
3 Unstoppable Stocks to Buy in August
Here are hot stocks to buy in a hot month.
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.
Here's How Much $1000 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today - Vertex Pharmaceuticals ( NASDAQ:VRTX )
Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 6.26% on an annualized basis producing an average annual return of 18.33%. Currently, Vertex Pharmaceuticals has a market capitalization of $117.41 billion.
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now
These growth stocks have plenty of room to run.
Stay Ahead of the Game With Vertex ( VRTX ) Q2 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of Vertex (VRTX) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients. multi-dosing is complete in first cohort ( 200 mg ) and single dosing is complete in second ...
Vertex Pharmaceuticals ( VRTX ) Ascends While Market Falls: Some Facts to Note
Vertex Pharmaceuticals (VRTX) closed at $468.41 in the latest trading session, marking a +1.64% move from the prior day.
Trump's pharmaceutical tariffs could affect some drugmakers more than others
AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
Harmony Biosciences Holdings, Inc. ( HRMY ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and Alyftrek and Journavx launches.
Vertex Pharmaceuticals Incorporated ( VRTX ) is Attracting Investor Attention: Here is What You Should Know
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
CRSP investors await the company's Q2 results with a focus on Casgevy sales growth and updates on gene-editing pipeline progress.
Vertex Pharmaceuticals ( VRTX ) Reports Next Week: Wall Street Expects Earnings Growth
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The 3 Things That Matter for Vertex Pharmaceuticals Now
Some of these developments could improve the company's prospects.
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.
What the Options Market Tells Us About CRISPR Therapeutics - CRISPR Therapeutics ( NASDAQ:CRSP )
High-rolling investors have positioned themselves bearish on CRISPR Therapeutics CRSP, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
Vertex Pharmaceuticals ( VRTX ) Rises Higher Than Market: Key Facts
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $476.95, signifying a +1.45% move from its prior day's close.
Zai Lab Limited ( ZLAB ) Stock Jumps 6.8%: Will It Continue to Soar?
Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Vertex Pharmaceuticals ( VRTX ) Outpaces Stock Market Gains: What You Should Know
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $470.13, denoting a +2.54% move from the preceding trading day.
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially positive data readouts.
3 Monster Stocks in the Making to Buy Right Now
Where can you find the next monster stocks? Check out the biotech space. It's not easy, but investors can sometimes find highly promising biotech stocks that are only in their early innings.Three Motley Fool contributors think they've identified monster stocks in the making.
